Welcome : Guest

ENDOMETRIOSIS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as -

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Debiopharm Group
Evotec AG

Click here to request a full list of companies covered in the report...

Code: MCP-6433
Price: $4950
Companies: 38
Pages: 181
Date: January 2018
Market Data Tables: 33
  Status: * New Report



TABLE OF CONTENTS


  ENDOMETRIOSIS (Complete Report) Pages : 181   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Endometriosis: An Introductory Prelude.....II-11$100
   Endometriosis Facts in a Nutshell.....II-2
Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs.....II-2
1$100
   Key Endometriosis Drugs on the Market.....II-3 1$100
   Table 1: Leading Endometriosis Drugs on the Market (2017E): Percentage Breakdown of Revenues for Depo-Provera, Lupron, Visanne, Zoladex and Others (includes corresponding Graph/Chart).....II-4
The Pipeline Review.....II-4
1$350
   Key Endometriosis Drugs in the Pipeline: 2017.....II-51$100
   Steady Growth Expected Over the Next Few Years.....II-6
Emerging Treatment for Endometriosis & Endometrial Cancer.....II-6
1$100
   Global Awareness Campaigns and Efforts.....II-71$100
   Uptrend in Healthcare Expenditure Creates Substantial Opportunities.....II-8 1$100
   Table 2: Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart).....II-91$350
   Table 3: Per Capita Healthcare Spending (in $) in Select Developed Countries for the Year 2016 (includes corresponding Graph/Chart).....II-10
Developed Regions Remain Primary Revenue Contributors.....II-10
1$350
   Table 4: Developed Regions Account for over 90% Share of World Endometriosis Drugs Market: Percentage Breakdown of Value Sales for Developed Regions and Developing Regions (2017E & 2022P) (includes corresponding Graph/Chart).....II-11
Developing Regions Exhibit Immense Growth Potential.....II-11
1$350
   Stable Economic Scenario to Augment Market Prospects.....II-12 1$100
   Table 5: World Real GDP Growth Rates in % (2016-2018P): Breakdown by Country/Region (includes corresponding Graph/Chart).....II-131$350
   Introduction.....II-14
Occurrence of Endometriosis in Women.....II-14
1$100
   Causes and Symptoms.....II-15
Causes.....II-15
Estrogen Theory.....II-15
Müllerianosis Theory.....II-15
Retrograde Menstruation Theory.....II-15
1$100
   Coelomic Metaplasia Theory.....II-16
Hereditary Factors.....II-16
Environmental Factors.....II-16
Dioxin Behavior in the Body.....II-16
1$100
   Birth Defects.....II-17
Other Causes.....II-17
Symptoms of Endometriosis.....II-17
1$100
   Reasons for Pain due to Endometriosis.....II-18
Endometriosis and Infertility.....II-18
Kinds of Endometriosis.....II-18
Reproductive Area Endometriosis.....II-18
Uterosacral/Presacral Nerve Endometriosis.....II-18
1$100
   Cul-de-Sac ("Pouch of Douglas") Endometriosis.....II-19
Gastrointestinal Endometriosis.....II-19
Pleural (lung/chest cavity/diaphragmatic) Endometriosis.....II-19
Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis.....II-19
Skin Endometriosis.....II-19
Sciatic Endometriosis.....II-19
Stages of Endometriosis.....II-19
1$100
   Diagnosis of Endometriosis.....II-20
Major Diagnostic Techniques.....II-20
Pelvic Exam.....II-20
Laparoscopy.....II-20
1$100
   Other Diagnostic Procedures.....II-21
A New Non-invasive Test for the Diagnosis of Endometriosis.....II-21
Endometriosis Markers.....II-21
Counseling of patients.....II-21
Recurrence of Endometriosis.....II-21
1$100
   Endometriosis & Infertility.....II-22
Miscarriage.....II-22
Endometriosis & Thyroid Autoimmunity.....II-22
Relationship between Endometriosis and Autoimmune Disease.....II-22
Endometriosis & Cancer.....II-22
Associations & Research Centers.....II-22
1$100
   The Endometriosis Association.....II-23
Endometriosis Research Center.....II-23
1$100
   Endometriosis & Available Treatment Options.....II-241$100
   Endometriosis Treatment Mechanisms: In a Nutshell.....II-251$100
   I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).....II-26
II. Hormonal Therapy.....II-26
Gonadotropin Releasing Hormone (Gnrh) Agonists.....II-26
1$100
   Select Major GnRH-Agonists for Endometriosis Treatment.....II-27
Lupron, Zoladex and Synarel – The Major Drugs.....II-27
AbbVie’s Lupron® (Leuprorelin).....II-27
AstraZeneca’s Zoladex® (Goserelin).....II-27
1$100
   Pfizer’s Synarel (Nafarelin Acetate).....II-28
Add-back Medication.....II-28
Progestogens.....II-28
1$100
   Select Major Progestins for Endometriosis Treatment.....II-29
Combined Oral Contraceptive Pill.....II-29
Danazol and Other Suppressive Steroids.....II-29
Chinese Herbs – More Effective than Danazol or Gestrinone.....II-29
1$100
   Aromatase Inhibitors.....II-30
III. Non-hormonal Therapy.....II-30
Anti-Angiogenic Agents.....II-30
Selective COX-2 Inhibitors.....II-30
TNF-Alpha Inhibitors.....II-30
IV. Surgical Techniques.....II-30
1$100
   V. Complementary Therapies.....II-31
Long-term Approach to Pain.....II-31
Lifestyle Modifications.....II-31
Chinese Herbs.....II-31
Treatment for Endometriosis-related Infertility.....II-31
1$100
   Hormonal Treatment.....II-32
Minimal to Mild Endometriosis.....II-32
Moderate-Severe Endometriosis.....II-32
Surgical Treatment.....II-32
Minimal-Mild Endometriosis.....II-32
Moderate-Severe Endometriosis.....II-32
1$100
   Treatment for Ovarian Endometriosis.....II-33
Surgical Vs. Medicinal Interventions.....II-33
Medicinal Interventions.....II-33
Advantages.....II-33
Disadvantages.....II-33
Surgery.....II-33
Advantages.....II-33
1$100
   Disadvantages.....II-34
In-vitro Fertilization.....II-34
Other Treatment.....II-34
1$100
   AbbVie and Neurocrine Bag US FDA Priority Review Clearance for Elagolix.....II-35
AbbVie Announces Results from Replicate Phase 3 Extension Studies for
  Elagolix.....II-35
Bayer Commences Enrolling Patients for Phase III Program to Study Vilaprisan’s
  Efficacy in Treating Symptomatic UF.....II-35
ObsEva to Commence Phase 2b EDELWEISS Clinical Trial of OBE2109.....II-35
Repros Keeps Proellex® Development Program on Partial Clinical Hold of FDA.....II-35
Aeterna Zentaris Halts Development of Zoptrex™.....II-35
1$100
   Evotec and Bayer’s Endometriosis Alliance Portfolio Advances into Phase I Clinical
  Development.....II-36
ObsEva Commences Phase 3 Clinical Program to Evaluate OBE2109 to Treat UF.....II-36
Myovant Achieves Positive Phase 3 Study Results for Relugolix in Treating UF.....II-36
Myovant Commences Phase 3 Program of Relugolix for Treating Endometriosis-Associated
  Pain.....II-36
Repros Therapeutics’ Achieves Positive Results from Proellex Phase II Study.....II-36
ValiRx Bags European Patent for VAL201.....II-36
1$100
   Virexxa Receives FDA Clearance to Proceed to Phase II.....II-37
OBE2109 by ObsEva Receives IND Clearance.....II-37
Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer
  Immunotherapies.....II-37
AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix.....II-37
ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201.....II-37
Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis
  Treatment.....II-37
Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution.....II-37
1$100
   Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment.....II-38
Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis
  Therapy.....II-38
Teleflex to Showcase its Surgical Solutions for Endometriosis.....II-38
ValiRx Plc Receives Patent Grant for VAL201.....II-38
1$100
   AstraZeneca Bags Commercial Rights to Zoladex.....II-39
Astellas Pharma to Acquire Ogeda.....II-39
Roivant Establishes New Global Headquarters in Basel.....II-39
Takeda and Roivant Partner to Form Myovant.....II-39
Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis
  Therapy.....II-39
ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for
  KLH-2109.....II-39
1$100
   AbbVie Inc. (USA).....II-40
Astellas Pharma Inc. (Japan).....II-40
AstraZeneca Plc (UK).....II-40
1$100
   Bayer AG (Germany).....II-41
Debiopharm Group (Switzerland).....II-41
1$100
   Evotec AG (Germany).....II-42
Kissei Pharmaceutical Co., Ltd. (Japan).....II-42
Neurocrine Biosciences, Inc. (USA).....II-42
1$100
   ObsEva SA (Switzerland).....II-43
Pfizer, Inc. (USA).....II-43
1$100
   Repros Therapeutics, Inc. (USA).....II-44
Roivant Sciences GmbH (Switzerland).....II-44
Takeda Pharmaceutical Company Limited (Japan).....II-44
1$100
   ValiRx plc (UK).....II-451$100
   Table 6: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-461$350
   Table 7: World Historic Review for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-471$350
   Table 8: World 14-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart).....II-481$350
   A. Market Analysis.....III-1
Largest Market for Endometriosis Drugs.....III-1
Endometriosis Associations Increase Awareness.....III-1
1$75
   Newer Diagnostic Methods Yet to Expand Across the Country.....III-2
Key Endometriosis Drugs on the Market.....III-2
Product Launches/Clinical Trials.....III-2
2$150
   Strategic Corporate Developments.....III-41$75
   Key Players.....III-52$150
   B. Market Analytics.....III-7
Table 9: The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-7
1$200
   Table 10: The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-81$200
   A. Market Analysis.....III-9
Product Launch.....III-9
Key Players.....III-9
1$75
   B. Market Analytics.....III-10
Table 11: Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-10
1$200
   Table 12: Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-111$200
   A. Market Analysis.....III-12
Clinical Trial.....III-12
Key Players.....III-12
2$150
   B. Market Analytics.....III-14
Table 13: Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-14
1$200
   Table 14: Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-151$200
   Market Analysis.....III-16
Market Analysis.....III-16
1$75
   Table 15: European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-171$200
   Table 16: European Historic Review for Endometriosis Drugs by Geographic Region/ Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-181$200
   Table 17: European 14-Year Perspective for Endometriosis Drugs by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart).....III-191$200
   A. Market Analysis.....III-20
Programmes to Maintain Endometriosis Database.....III-20
1$75
   B. Market Analytics.....III-21
Table 18: French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-21
1$200
   Table 19: French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-221$200
   A. Market Analysis.....III-23
Clinical Trials.....III-23
Strategic Corporate Development.....III-23
Key Players.....III-23
2$150
   B. Market Analytics.....III-25
Table 20: German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-25
1$200
   Table 21: German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-261$200
   Market Analysis.....III-27
Table 22: Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-27
1$200
   Table 23: Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-281$200
   A. Market Analysis.....III-29
Product Launches/Clinical Trials.....III-29
Key Players.....III-29
2$150
   B. Market Analytics.....III-31
Table 24: The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-31
1$200
   Table 25: The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-321$200
   Market Analysis.....III-33
Table 26: Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-33
1$200
   Table 27: Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-341$200
   A. Market Analysis.....III-35
Product Launches/Clinical Trials.....III-35
1$75
   Strategic Corporate Developments.....III-36
Key Players.....III-36
2$150
   B. Market Analytics.....III-38
Table 28: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-38
1$200
   Table 29: Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
The Rapidly Growing Market.....III-40
Endometriosis Therapeutics in Australia.....III-40
1$75
   B. Market Analytics.....III-41
Table 30: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-41
1$200
   Table 31: Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-421$200
   A. Market Analysis.....III-43
Product Launch.....III-43
B. Market Analytics.....III-43
Table 32: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-43
1$200
   Table 33: Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-441$200
  
Total Companies Profiled: 38 (including Divisions/Subsidiaries - 40)

Region/Country Players

The United States 11 Canada 3 Japan 6 Europe 15 France 1 Germany 3 The United Kingdom 2 Rest of Europe 9 Asia-Pacific (Excluding Japan) 4 Middle-East 1
Click here to request a full table of contents and more details on this project.